Texas Children's Cancer and Hematology Center

Clinical Trials and Novel Therapies

GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

Our study evaluates the safety, persistence and antitumor activity of T cells bearing a 2nd generation GD2-specific chimeric antigen receptor (CAR) augmented by a constitutively active interleukin-7 receptor gene (C7R) to the CAR T cells for treatment of  patients with H3K27M-altered diffuse midline gliomas (DMG) and other recurrent high grade CNS tumors expressing GD2. The goal is to improve persistence of the CAR T cells using C7R.

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)

Study aims to determine the optimal safe dosage of GD2-CAR NKT cells (GINAKIT cells), assess their impact on neuroblastoma tumors, duration of detection in patient blood, and their influence on neuroblastoma outcomes in children.

Vinblastine/Prednisone versus Single Therapy with Cytarabine for Langerhans Cell Histiocytosis (LCH)

Study for patients newly diagnosed with Langerhan's cell histiocytosis to compare vinblastine/prednisone  versus cytarabine (LCH-REASON).

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Phase 1 immunotherapy trial using next generation CD30.CAR T cells  for refractory lymphoma (Hodgkin or non-Hodgkin, including ALCL) (RELY 30).

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)

Phase 1 trial using next generation CD5.CAR T cells for recurrent T-cell leukemia/lymphoma (MAGENTA).

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

Phase 1 study of a novel trivalent CAR-T cell therapy for patients with refractory or recurrent B cell acute lymphoblastic leukemia (+CD19, +CD20 and/or +CD22)

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination with Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)

Phase 1 immunotherapy trial for children with relapsed or refractory sarcoma using a combination of HER2-CAR T cells with checkpoint blockade (HEROS 3.0).

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders (NACHO COBI)

Frontline study of cobimetinib in patients with recurrent or refractory histiocytic diseases (NACHO COBI).

New immunotherapy for children with solid tumors including liver, kidney and additional rare cancers

Phase 1 immunotherapy trial using 15.GPC3-CAR T cells for children with solid tumors, including liver, kidney and other rare cancers.

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells (CRIMSON)

Phase 1 cell therapy for children with high-risk T-cell malignancies using CD7-specific CAR expressed on autologous T cells (CRIMSON).

Immunotherapy For Children With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells (CARE)

This clinical study will test the effect of 21.15.GPC3-CAR T cells in patients with solid tumors including Hepatoblastoma, Hepatocellular Carcinoma, Wilms Tumor, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Rhabdomyosarcoma, Liposarcoma and Embryonal Sarcoma of Liver that express a molecule called GPC3 on their surface.

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (ONITT)

Phase 1 study of irinotecan liposomal with talazoparib or temozolomide in children with recurrent solid tumors or Ewing sarcoma (ONITT).

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (EPIK-P2)

A Phase 2 study for alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (EPIK-P2).

Evaluation of the Safety and Efficacy of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis

Evaluation of ELA026 monoclonal antibody for safety and efficacy as a treatment for patients with secondary hemophagocytic lymphohistiocytosis.

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (MASter-1)

Phase 2 trial for MAS825 in patients with monogenic IL-18 driven autoinflammatory diseases, including NLRC4-GOF, XIAP deficiency or CDC42 mutations (MASter-1).

HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children with Ependymoma (PBTC-059)

A multi-center HER2-CAR T-cell immunotherapy trial for children with relapsed or refractory ependymoma (PBTC-059).